

# Press Release

**ProStrakan Group plc**

**ProStrakan Announces Canadian Regulatory Filing of Abstral**

**Galashiels, UK. 4<sup>th</sup> February 2010:** ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that the New Drug Submission made by ProStrakan's Canadian partner, Paladin Labs Inc. ("Paladin"), for Abstral has been accepted for review by Health Canada, the Canadian Government Department with responsibility for public health.

Abstral is a new, rapidly-disintegrating, sub-lingual (under the tongue) formulation of fentanyl, a long-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for their chronic pain.

ProStrakan signed an exclusive licence and distribution agreement for Abstral in Canada with Paladin in December 2008. Under the terms of the agreement, which also covered Sancuso (ProStrakan's transdermal patch for the prevention of chemotherapy-induced nausea and vomiting), ProStrakan received from Paladin an undisclosed upfront payment, with further milestone payments due on product approval and the subsequent achievement of certain sales targets.

The submission has been granted priority review status by Health Canada and review of the application is therefore expected to conclude in 180 days.

Commenting on today's announcement, Dr Wilson Totten, Chief Executive of ProStrakan, said:

"The successful filing of Abstral in Canada by Paladin exemplifies ProStrakan's strategy of partnering with high quality organisations in countries outside our own core geographic focus. Through Paladin, we hope that Abstral will soon be made available to clinicians and their patients in this important market."

**Ends**

**For further enquiries, please contact:**

<b>ProStrakan</b>	+44 (0) 1896 664000
Dr Wilson Totten, Chief Executive	
Allan Watson, Chief Financial Officer	
Callum Spreng, Corporate Communications	
<b>Brunswick Group</b>	+44 (0) 20 7404 5959
Jon Coles / Justine McIlroy	

**About ProStrakan:**

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

[www.prostrakan.com](http://www.prostrakan.com)